MetaCap

IGC Pharma (IGC) vs TherapeuticsMD (TXMD)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

TherapeuticsMD (TXMD) has outperformed IGC Pharma (IGC) over the past year, losing 3.9% versus a loss of 47.5%. Over five years, IGC leads with a -87.6% price change compared with -94.1% for TXMD. TherapeuticsMD is the larger company by market cap ($19.8 million vs $19.6 million), about 1.0 times the size.

TherapeuticsMD converts more of its revenue into profit, with a net margin of -18.8% versus -560.3%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IGC-47.50%TXMD-3.93%
+61%+4%-53%
Nov 21, 20251 yearNov 20, 2026
IGC-88.25%TXMD-94.00%
+7%-48%-102%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IGC versus TXMD key metrics
MetricIGCTXMD
Share price$0.168$1.71
Market cap$19.60M$19.79M
1-day change-8.70%-5.52%
YTD return-40.00%+4.91%
1-year return-47.50%-3.93%
5-year return-87.65%-94.10%
P/E ratio (TTM)—171.00
Forward P/E—4.89
EPS (TTM)$-0.07$0.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$1.27M$3.02M
Revenue growth (YoY)-5.50%+71.61%
Net income (latest FY)$-7.12M$-569.00K
Gross margin48.70%—
Operating margin-585.84%-145.27%
Net margin-560.35%-18.83%
52-week high$0.36$2.95
52-week low$0.08$1.43
Distance from 52-week high-53.33%-42.03%
Analyst consensusnone—
Avg. price target upside+3471.43%—
Average volume615.25K24.50K
Shares outstanding116.69M11.57M
Employees701
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • TXMD has outperformed IGC by 43.6 percentage points over the past year.
  • TherapeuticsMD is more profitable, keeping -18.8 cents of every revenue dollar as net income versus -560.3 cents for IGC Pharma.
  • TherapeuticsMD grew revenue faster in its latest fiscal year (+71.61% vs -5.50%).

About IGC Pharma

IGC stock →

IGC Pharma, Inc., a clinical stage pharmaceutical company, develops novel therapeutic candidates for neuropsychiatric and neurodegenerative disorders, with a primary focus on Alzheimer's disease in the United States and Colombia. The company's lead product is IGC-AD1 that is in Phase II clinical trial for the treatment of agitation in dementia due to Alzheimer's.

Health Care · Biotechnology: Pharmaceutical Preparations · 70 employees

About TherapeuticsMD

TXMD stock →

TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 1 employees

IGC vs TXMD FAQ

Which is bigger, IGC Pharma or TherapeuticsMD?

TherapeuticsMD (TXMD) is larger, with a market capitalization of $19.79M compared with $19.60M for IGC Pharma (IGC).

Which stock has performed better over the past year, IGC or TXMD?

TXMD returned -3.93% over the past 12 months, compared with -47.50% for IGC (price return, excluding dividends). Past performance does not predict future results.

Are IGC Pharma and TherapeuticsMD in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons